[Form 4] LeMaitre Vascular, Inc. Insider Trading Activity

Rhea-AI Filing Summary

LeMaitre Vascular (LMAT) Form 4: Director Martha Shadan reported acquisitions of dividend equivalent rights on 09/04/2025 that accrued on prior equity awards. The filing lists five separate accrual entries tied to restricted stock units and performance share units granted on 12/12/2022, 12/8/2023 and 12/6/2024. Each entry shows fractional amounts of economic share equivalents acquired (0.4173; 0.4173; 0.7138; 0.8546; 0.8697) at a reported price of $0, with ownership reported as Direct (D). The Form is signed by Nathan Ulrich on 09/08/2025.

Insights

Securities Analyst

TL;DR: Insider acquired small fractional dividend equivalent rights from prior RSU/PSU awards; transactions appear non-cash and routine.

The reporting person, identified as a director, recorded five accruals of dividend equivalent rights on 09/04/2025 that vest proportionately with underlying restricted stock units and performance share units granted on specified prior grant dates. Each accrual is recorded at a price of $0 and shown as direct beneficial ownership. The amounts are fractional (less than one share each) and relate to economic equivalents rather than new stock issuances. There is no cash consideration and no change in control indicated.

Corporate Governance Expert

TL;DR: Reporting aligns with compensation plan mechanics; entries document dividend equivalents vesting with existing equity awards.

The Form 4 discloses dividend equivalent rights tied to RSU and PSU awards from 2022, 2023 and 2024 grant dates, vesting proportionately with those awards. Each line item specifies the accrual amount, underlying common stock equivalent and lists the ownership form as direct. The filing follows Section 16 reporting requirements and includes a signature and date, indicating timely disclosure of these compensation-related accruals rather than open-market trades.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SHADAN MARTHA

(Last) (First) (Middle)

C/O LEMAITRE VASCULAR, INC.

63 SECOND AVENUE

(Street)

BURLINGTON MA 01803

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LEMAITRE VASCULAR INC [ LMAT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/04/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Dividend Equivalent Rights	(1)	09/04/2025		A		0.4173		(1)	(1)	Common Stock	0.4173	$0	6.5156	D
Dividend Equivalent Rights	(2)	09/04/2025		A		0.4173		(2)	(2)	Common Stock	0.4173	$0	5.5269	D
Dividend Equivalent Rights	(3)	09/04/2025		A		0.7138		(3)	(3)	Common Stock	0.7138	$0	5.3975	D
Dividend Equivalent Rights	(4)	09/04/2025		A		0.8546		(4)	(4)	Common Stock	0.8546	$0	5.8691	D
Dividend Equivalent Rights	(5)	09/04/2025		A		0.8697		(5)	(5)	Common Stock	0.8697	$0	2.9094	D

Explanation of Responses:

1. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/12/22 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

2. These dividend equivalent rights accrued on a Performance Share Unit (PSU) award granted on 12/12/22 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

3. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/8/23 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

4. These dividend equivalent rights accrued on a Performance Share Unit (PSU) award granted on 12/8/23 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

5. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/6/24 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

	/s/ Nathan Ulrich	09/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Martha Shadan report on the Form 4 for LMAT?

The Form 4 reports acquisitions of dividend equivalent rights on 09/04/2025 that accrued on prior RSU and PSU awards; each entry is recorded at $0 and as Direct ownership.

How many dividend equivalent accruals are disclosed and what are the amounts?

Five accruals are disclosed with amounts of 0.4173, 0.4173, 0.7138, 0.8546, and 0.8697 (each expressed as the economic equivalent of one share).

Which grant dates produced these dividend equivalents?

The filing ties accruals to awards granted on 12/12/2022, 12/8/2023, and 12/6/2024.

Was any cash paid for these transactions?

No cash was reported; each dividend equivalent right is listed at a price of $0.

When was the Form 4 signed and who signed it?

The form bears the signature line "/s/ Nathan Ulrich" with date 09/08/2025.